Recombinant interferon α-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: A 3-year trial with recombinant interferon-α and 5-year follow-up

Melanoma Research

Volumn 17, Issue 3, 2007, Pages 177-183

  Rusciani, Luigi ^a   Proietti, Ilaria ^a   Paradisi, Andrea ^a   Rusciani, Antonio ^b   Guerriero, Giuseppe ^a   Mammone, Alessia ^c   De Gaetano, Andrea ^c   Lippa, Silvio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CNR   (Italy)

Author keywords

Adjuvant therapy; Coenzyme Q10; Follow up; Interferon alpha; Melanoma

Indexed keywords

PARACETAMOL; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; UBIDECARENONE;

ADULT; AGED; APPLICATION SITE DISCOMFORT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COURSE EVALUATION; DISEASE COURSE; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; MELANOMA; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COENZYMES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; LOGISTIC MODELS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; UBIQUINONE; VITAMINS;

EID: 34249091108     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32818867a0     Document Type: Article

References (92)

1. National Cancer Institute. 51-year trends in U.S. cancer death rates. In: SEER cancer statistics review, 1975-2000. (Accessed August 9, 2004, at http://seer.cancer.gov/cst/1975_2000/results_merged/topic_inc_mor_trends. pdf.)
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
3. Albert LS, Rhodes AR, Sober AJ. Dysplastic melanocytic nevi and cutaneous melanoma: markers of increased melanoma risk for affected persons and blood relatives. J Am Acad Dermatol 1990; 22:69-75.
4. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician 2000; 62:357-368, 375-376, 381-382.
5. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A Multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1:126-134.
6. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992; 8:400-414.
7. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20:1818-1825.
8. Kirkwood JM, Ernstoff MS. Role of interferons in the therapy of melanoma. J Invest Dermatol 1990; 95:180S-184S.
9. Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995; 75(2 Suppl):726-734.
10. Argarwala SS, Kirkwood JM. Potential use of interferon alpha 2 as adjuvant therapy in cancer. Ann Surg Oncol 1995; 2:365-371.
11. Luke LG, Tyring SK, Wagner RF. Possible role of adjuvant therapy for thin malignant melanoma. Cutis 1992; 50:377-379.
12. Argarwala SS, Kirkwood JM. Update on adjuvant interferon therapy for high-risk melanoma. Oncology 2002; 16:1177-1187.
13. Agarwala SS, Kirkwood JM. Forum (Genova). 2000; 10:230-239.
14. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16:1425-1429.
15. Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351:1905-1910.
16. O'Day SJ, Kim CJ, Reintgen DS. Metastatic melanoma: chemotherapy to biochemotherapy. Cancer Control 2002; 9:31-37.
17. Aapro MS. Advances in systemic treatment of malignant melanoma. Eur J Cancer 1993; 29A:613-617.
18. Krasagakis K, Garbe C, Zouboulis CC, Orfanos CE. Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res 1995; 139:169-182.
19. Poetsch M, Dittberner T, Woennchaus C. Can different genetic changes characterize histogenetic subtypes and biologic behavior in sporadic malignant melanoma of the skin? Cell Mol Life Sci 2003; 60:1923-1932.
20. Legha SW. Interferons in the treatment of malignant melanoma. Cancer 1986; 57:1675-1677.
21. Johnson JW, Smith TM II, Nelson BR, Chang A. Current therapy for cutaneous melanoma. J Am Acad Dermatol 1995; 32:689-706.
22. MC Leod GR, Thomson DB, Hersey P. Clinical evaluation of interferons in malignant melanoma. J Invest Dermatol 1990; 95:185s-187s.
23. Lanza L, Peraino L, Bosco O, Contini P, Filaci G, Setti M, et al. Interferons up-regulate with different potency HLA class I antigen expression in m14 human melanoma cell line. Possible interaction with glucocorticoid hormones. Cancer Immunol Immunother 1995; 41:23-28.
24. Rodriguez-Villanueva J, McDonnel TJ. Induction of apoptotic cell death in non-melanoma skin cancer by interferon alpha. Int J Cancer 1995; 61: 110-114.
25. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons: mechanism of action and clinical application. JAMA 1991; 266:1375-1383.
26. Linge C, Gewert D, Rossmann C, Bishop JA, Crowe JS. Interferon system defects in human malignant melanoma. Cancer Res 1995; 55:4099-4104.
27. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6:34-55.
28. Festenstein GN, Heaton FW, Lowe JS, Morton RA. A constituent of the unsaponifiable portion of animal tissue lipids (lambda max. 272 m mu). Biochem J 1955; 59:558-566.
29. Crane FL, Hatefi Y, Lester RL, Widmer C. Isolation of a quinone from beef heart mitochondria. Biochim Biophys Acta 1957; 25:220-221.
30. 10. J Am Coll Cutr 2001; 20:591-598.
31. Mitchell P. Possible molecular mechanisms of the protonmotive function of cytochrome systems. J Theor Biol 1976; 62:327-367.
32. Beyer RE, Nordenbrand K, Ernster L. The role of coenzyme Q as a mitochondrial antioxidant: a short review. In: Folkers K, Yamamura Y, editors. Biomedical and clinical aspects of coenzyme Q. Vol. 5. Amsterdam, The Netherlands: Elsevier Science Publishers B V (Biomedical Division); 1986, pp. 17-24.
33. Bliznakov EG, Casey AC. Effect of exogenous ubiquinone-10 on the ubiquinone pool of liver and spleen of mice. Biochim Biophys Acta 1974; 362:326-333.
34. Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 1998; 247:166-170.
35. Yamamoto Y, Yamashita S. Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol Aspects Med 1997; 18 (Suppl):S79-S84.
36. Ernster L, Forsmark-Andrée P. Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Invest 1993; 71(8 Suppl):S60-S65.
37. 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 1974; 24:19-22.
38. 10. Am J Health Syst Pharm 1999; 56:519-21.
39. 10 in animal models and serious deficiency in patients with cancer. Biochem Biophys Res Commun 1997; 234:296-299.
40. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the AJCC staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3641.
41. Houghton A, Coit D, Bloomer W, Buzaid A, Chu D, Eisenburgh B, et al. Melanoma practice guidelines. Nat Compr Cancer Network. Oncology 1998; 12:153-177.
42. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126:438-441.
43. Urist MM. Surgical management of primary cutaneous melanoma. CA Cancer J 1996; 46:217-224.
44. Breslow A. Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902-908.
45. Johnson M. Neoplastic fever. Palliat Med 1996; 10:217-224.
46. Doveil GC, Fierro MT, Novelli M, Appino A, Bertero M, Quaglino P, Bernengo MG. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance. Dermatology 1995; 191:234-239.
47. Cascinelli N, Bufalino R, Morabito A, Mackie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994; 343:913-914.
48. Pemberger S, Jagsch R, Frey E, Felder-Puig R, Gadner H, Kryspin-Exner I, Topf R. Quality of life in long-term childhood cancer survivors and the relation of late effects and subjective well-being. Support Care Cancer 2005; 13:49-56.
49. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20:3703-3718.
50. Dean GE, Spears L, Ferrell BR, Quan WD, Groshon S, Mitchell MS. Fatigue in patients with cancer receiving interferon alpha. Cancer Pract 1995; 3:164-172.
51. Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 2002; 20:1311-1318.
52. Tsao H, Sober AJ. Melanoma treatment update. Dermatol Clin 2005; 23:323-333.
53. Rusciani L, Petraglia S, Alotto M, Calvieri S, Vezzoni G. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer 1997; 12:2354-2360.
54. Slinguff CL Jr, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer 1992; 70:1917-1927.
55. 10 in health and disease. Eur J Clin Nutr 1999; 53:764-770.
56. 10. Res Commun Chem Pathol Pharmacol 1982; 38:335-338.
57. Bliznakov E, Casey A, Premuzic E. Coenzymes Q stimulants of the phagocytic activity in rats and immune response in mice. Experientia 1970; 26:953-954.
58. 10 enhances the recovery of human lymphocytes from oxidative DNA damage. FASEB J 2001; 15:1425-1427.
59. 10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol 2006; 54:234-241.
60. Picardo M, Grammatico P, Roccella F, Roccella M, Grandinetti M, Del Porto G, Passi S. Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. J Invest Dermatol 1996; 3:322-326.
61. Brar SS, Kennedy TP, Whorton AR, Sturrock AB, Huecksteadt TP, Ghio AJ, Hoidal JR. Reactive oxygen species from NAD(P)H: quinone oxidoreductase constitutively activate NF-kB in malignant melanoma cells. Am J Physiol Cell Physiol 2001; 280:659-676.
62. 10 Drug Surveillance Investigators. Mol Aspects Med 1994; 15 (Suppl):S287-S294.
63. 10. Cancer Treat Rep 1978; 62:887-891.
64. 10 on immunorestoration with Mycobacterium bovis BCG in tumor bearing mice. Gann 1978; 69:493-497.
65. 10. Res Commun Chem Pathol Pharmacol 1978; 19:485-490.
66. 10 and four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem Biophys Res Commun 1996; 224:358-361.
67. 10 and lipid-related gene induction in HeLa cells. Am J Obstet Gynecol 2004; 190:1432-1434.
68. Quiles JL, Farquharson AJ, Ramirez-Tortosa MC, Grant I, Milne L, Huertas JR, et al. Coenzyme Q differentially modulates phospholipid hydroperoxide glutathione peroxidase gene expression and free radicals production in malignant and non-malignant prostate cells. Biofactors 2003; 18:265-270.
69. Bruge F, Tiano L, Cacciamani T, Principi F, Littarru GP. Effect of UV-C mediated oxidative stress in leukemia cell lines and its relation to ubiquinone content. Biofactors 2003; 18:51-63.
70. 10: Could it have a role in cancer management? Biofactors 1999; 9:365-370.
71. 10. Biochem Biophys Res Commun 1993; 192:241-245.
72. 10 and regression of metastases. Biochem Biophys Res Commun 1995; 212:172-177.
73. 10. Mol Aspects Med 1994; 15: 231-240.
74. 10. Biochem Biophys Res Commun 1994; 8:1504-1508.
75. 10 concentrations and antioxidant status in tissue of breast cancer patients. Clin Biochem 2000; 33:279-284.
76. 10 in cancer patients. Ugeskr Laeger 1994; 156:823.
77. 10 levels in cancer cell lines. Free Radic Biol Med 2006; 40:1293-1302.
78. Perumal SS, Shanthi P, Sachdanandam P. Energy-modulating vitamins: a new combinatorial therapy prevents cancer cachexia in rat mammary carcinoma. Br J Nutr 2005; 93:901-909.
79. 10 on the status of lipid peroxidation and antioxidants in DMBA induced breast cancer. Mol Cell Biochem 2005; 273:151-160.
80. 10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study. Eur Urol 2005; 47:433-439.
81. 10: effects on lipid peroxidation and antioxidants in mitochondria. Chem Biol Interact 2005; 152:49-58.
82. 10, and wheat grass therapy for primary peritoneal cancer. J Altern Complement Med 2005; 11:161-165.
83. Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005; 25:CD003917.
84. 10 for the prevention and treatment of cancer. Evid Rep Technol Assess (Summ) 2003:1-3.
85. 10 for improved tolerability of cancer treatments: a systematic review. J Clin Oncol 2004; 22:4418-4424.
86. Conklin KA. Cancer chemotherapy and antioxidants. J Nutr 2004; 134:3201S-3204S.
87. Morre DJ, Morre DM. Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases. Free Radic Res 2003; 37:795-808.
88. 10 and tocopherols in cervical intraepithelial neoplasia and cervical cancer. Eur J Cancer Prev 2003; 12:321-326.
89. Lesperance ML, Olivotto IA, Forde N, Zhao Y, Speers C, Foster H, et al. Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study. Breast Cancer Res Treat 2002; 76: 137-143.
90. Moehrle M, Kraemer A, Schippert W, Garbe C, Rassner G, Breuninger H. Clinical risk factors and prognostic significance of local recurrence in cutaneous melanoma. Br J Dermatol 2004; 151:397-406.
91. Schmid-Wendtner MH, Baumert J, Eberle J, Plewig G, Volkenandt M, Sander CA. Disease progression in patients with thin cutaneous melanomas (tumor thickness < =0.75 mm): clinical and epidemiological data from Tumour Center Munich 1977-98. Br J Dermatol 2003; 149:788-793.
92. Kalady MF, White RR, Johnson JL. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 2003; 238:528-537.